Gaelle Stadtler - Transgene VP HR

TNG Stock  EUR 0.73  0.02  2.82%   

Insider

Gaelle Stadtler is VP HR of Transgene SA
Age 40
Phone33 3 88 27 91 00
Webhttps://www.transgene.fr

Transgene Management Efficiency

The company has return on total asset (ROA) of (0.1628) % which means that it has lost $0.1628 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.3623) %, meaning that it generated substantial loss on money invested by shareholders. Transgene's management efficiency ratios could be used to measure how well Transgene manages its routine affairs as well as how well it operates its assets and liabilities.

Similar Executives

Showing other executives

INSIDER Age

Christian FASSOTTEAB Science SA
N/A
Pascal CaiseyGenfit
55
DVM MBAInnate Pharma
58
Harshad KULKARNIAB Science SA
N/A
JeanChristophe MarcouxGenfit
46
Alain MBAAB Science SA
N/A
AnneJuliette MANanobiotix SA
49
Yves MDAB Science SA
N/A
Laurent MBAAB Science SA
N/A
Stefanie MagnerGenfit
42
Brandon OwensNanobiotix SA
N/A
Mondher MDInnate Pharma
65
Frederic MBAInnate Pharma
48
Kathryn McNeilNanobiotix SA
48
Pr StaelsGenfit
60
Odile BelzunceInnate Pharma
43
Thomas BaetzGenfit
49
Laurent LevyNanobiotix SA
50
Sarah GaubertNanobiotix SA
N/A
Marc BonnevilleInnate Pharma
63
Earl BergeyNanobiotix SA
68
Transgene SA, a biotechnology company, designs, develops, and produces therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. The company was founded in 1979 and is headquartered in Illkirch-Graffenstaden, France. TRANSGENE operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 132 people. Transgene SA (TNG) is traded on Euronext Paris in France and employs 143 people.

Management Performance

Transgene SA Leadership Team

Elected by the shareholders, the Transgene's board of directors comprises two types of representatives: Transgene inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Transgene. The board's role is to monitor Transgene's management team and ensure that shareholders' interests are well served. Transgene's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Transgene's outside directors are responsible for providing unbiased perspectives on the board's policies.
Maud MD, VP Officer
Eric Quemeneur, Ex Officer
Gaelle Stadtler, VP HR
JeanPhilippe Del, VP CFO
Hedi Brahim, CEO Director
Elisabetta Castelli, Director Relations
Lucie Larguier, Director IR
Steven RPh, VP Officer
LLM JD, Gen VP
Philippe Slos, Head Laboratory

Transgene Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Transgene a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Transgene Stock

Transgene financial ratios help investors to determine whether Transgene Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Transgene with respect to the benefits of owning Transgene security.